Systemic and neurological uses of immunosuppressive agents;Immunosuppresseurs : Usages systémiques et neurologiques

Revue Medicale Suisse

Volumn 9, Issue 384, 2013, Pages 915-921

  Schnider, Caroline ^a   Seebach, Joerg D ^b   Ribi, Camillo ^c   Spertini, François ^c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Service d'immunologie et d'allergologie   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; AUTOIMMUNE DISEASE; DRUG MEGADOSE; DRUG SAFETY; IMMUNOSUPPRESSIVE TREATMENT; REMISSION;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NERVOUS SYSTEM DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878181612     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-Associated vasculitis and renal involvement : A prospective, randomized study. Arthritis Rheum 1998; 41:1835-44.
2. Steinberg AD, Steinberg SC. Long-Term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
3. Guillevin L, Cohen P, Mahr A. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors : A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
4. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis asso-ciated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
5. Mariette X. Les Anti-TNF dans les maladies autoimmunes et les vascularites. Flammarion Médecinesciences, 2004.
6. Keane J, Gershon S, Wise R, et al. Tuberculosis associated with infliximab, a tumor necrosis factor αneutralizing agent. N Engl J Med 2001;35:1098.
7. Charles P, Smeenk R, De Jong J, et al. Assesment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor. Arthritis Rheum 2000;43:2383-90.
8. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-Tumour necrosis factor alpha therapy : A French national survey. Arthritis Res Ther 2005;7:R545-51.
9. Chappuis S, Ribi C, Spertini F. Anti-TNFα : effets indésirables et implications pratiques. Rev Med Suisse 2013;9:12-6.
10. Sarwar H, McGrath H, Espinoza L. Successful treatment of long-standing neuro-Béhçet's disease with infliximab. J Rheumatol 2005;32:181-3.
11. Ribi C, Sztajzel R, Delavelle J, et al. Efficacy of TNFα blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry 2005; 76:1733-5.
12. Licata G, Pinto A, Tuttolomondo A, et al. Anti-Tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis 2003;62:280-1.
13. Pipitone N, Boiardi L, Salvarani C. Infliximab for Neuro-Behçet's disease : Report of two cases. Clin Exp Rheumatol 2006;24:34.
14. Sfikakis P, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease -review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41.
15. Sfikakis P, Theodossiadis P, Katsiari C, et al. Effect of infliximab on sight-Threatening panuveitis in Behcet's disease. Lancet 2001;358:295-6.
16. Niccoli L, Nannini C, Benucci M, et al. Long-Term efficacy of infliximab in refractory posterior uveitis of Behcet's disease : A 24-month follow-up study. Rheumatology (Oxford) 2007;46:1161-4.
17. Pereira J, Anderson N, McAuley D, et al. Medically refractory neurosarcoidosis treated with infliximab. Intern Med J 2011;41:354-7.
18. Santos E, Shaunak S, Renowden A, et al. Treatment of refractory neurosarcoidosis with infliximab. J Neurol Neurosurg Psychiatry 2010;81:241-6.
19. Sodhi M, Pearson K, White S, et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009;103:268-73.
20. Almeida Dutra L, Braga-Neto P, Araújo Oliveira R, et al. Neurosarcoidosis : Guidance for the general neurologist. Arq Neuropsiquiatr 2012;70:293-9.
21. Group Wegener's granulomatosis Etanercept Trial (WGET) Research. Etanercept plus standard therapy for Wegerner's granulomatosis. N Engl J Med 2005;352:351-61.
22. Holle J, Gross W. Neurological involvement in Wegener's granulomatosis. Curr Opin Rheumatol 2011; 23:7-11.
23. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome : Results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270-6.
24. Sankar V, Brennan M, Kok M. Etanercept in Sjögren's syndrome : A twelve week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
25. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.
26. Iannone F, Scioscia C, Falappone P, et al. Use of etanercept in the treatment of dermatomyositis : A case series. J Rheumatol 2006;33:1802-4.
27. Postal M, Costallat L, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol 2012;2012:578-641.
28. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-Alpha blockade with infliximab in patients with systemic lupus erythematosus : Longterm follow-up of 13 patients. Rheumatology 2009;48: 1451-4.
29. Carson K, Evens A, Richey E, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients : A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
30. Stone J, Merkel P, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med 2010;363:221-32.
31. Jones R, Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis. N Engl J Med 2010;363:211-20.
32. Meijer J, Meiners P, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome : A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
33. Mekinian A, Ravaud P, Hatron P, et al. Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement : Results from the AIR registry. Ann Rheum Dis 2012;71:84-7.
34. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis : A randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
35. Tournadre A, Dubost J, Soubrier M. Treatment of inflammatory muscle disease in adults. Joint Bone Spine 2010;77:390-4.
36. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-To-severely active systemic lupus erythematosus : The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62: 222-33.
37. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis : The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
38. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus : A randomised, placebocontrolled, phase 3 trial. Lancet 2011;377:721-31.